Nemucore Medical Innovations, Inc.
Leukemia
Aml
Blood cancer
Acute myeloid leukemia
Cancer
Research
Founded in 2008
Wellesley, Massachusetts
Nemucore Medical Innovations, Inc. information
We envision a world where patients with cancer receive an effective drug the first time. About 30% of patients have mutations in their DNA that indicate they'll respond well to certain drugs; we develop drugs for the other 70%. We combined our drug, NMI-900, with a unique diagnostic that measures RNA rather than DNA. Our approach has the potential to select the right patient, improve survival, and...
We envision a world where patients with cancer receive an effective drug the first time. About 30% of patients have mutations in their DNA that indicate they'll respond well to certain drugs; we develop drugs for the other 70%. We combined our drug, NMI-900, with a unique diagnostic that measures RNA rather than DNA. Our approach has the potential to select the right patient, improve survival, and limit side effects. In 5 years, we look forward to regulatory approval in AML and helping patients.Find out more at:https://wefunder.com/nemucore.medical.innovations.inc
Employees
Looking for a particular Nemucore Medical Innovations, Inc. Employee?
Employee Metrics
Nemucore Medical Innovations, Inc.'s financial review
Nemucore Medical Innovations, Inc.'s Revenue (Yearly)
24.0M
Employees
4
Technologies
Alumni
Srinivas Ganta
CMC Team Lead (Senior Pharmaceutical Quality Assessor & Application Technical Lead)FDA
Employees
Looking for a particular Nemucore Medical Innovations, Inc. Employee?
Nemucore Medical Innovations, Inc.'s financial review
Nemucore Medical Innovations, Inc.'s Revenue (Yearly)
24.0M
Employees
4
Prospect on LinkedIn
Find verified emails and direct dial mobile numbers of contacts on LinkedIn, and sync them with your CRM instantly
